Stoke Therapeutics Newsroom

Stoke Therapeutics (NASDAQ:STOK) Pulls Back 9.1% This Week, but Still Delivers Shareholders Impressive 136% Return Over 1 Year

Simply Wall StDec 14 08:53 ET

Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 13,945 Shares

Quiver QuantitativeDec 10 19:16 ET

Express News | Cantor Fitzgerald Reiterates Overweight on Stoke Therapeuticsto Overweight

BenzingaDec 10 08:55 ET

Stoke Therapeutics Analyst Ratings

BenzingaDec 10 08:53 ET · Ratings

Stoke Therapeutics: Promising Developments in Seizure Treatment Bolster Buy Rating

TipRanksDec 10 01:06 ET · Ratings

Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsDec 9 14:32 ET · Ratings

H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsDec 9 11:31 ET · Ratings

BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $29

Moomoo NewsDec 9 06:31 ET · Ratings

Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)

TipRanksDec 9 06:30 ET · Ratings

Stoke Therapeutics Reports Durable Seizure Control With Zorevunersen in Dravet Patient

MT NewswiresDec 6 13:06 ET

STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

Zacks Dec 5 09:40 ET

GeneDx Announces Biogen, Praxis Precision Medicines And Stoke Therapeutics As The Founding Partners To Its Patient Access Program For Pediatric Epilepsy, Which Provides Access To Whole Exome Sequencing.

BenzingaDec 5 08:54 ET

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients With New Partners

BusinesswireDec 5 08:30 ET

Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday

BenzingaDec 4 10:55 ET

Stoke Therapeutics' Zorevunersen Gets FDA Breakthrough Therapy Status in Dravet Syndrome

MT NewswiresDec 4 08:11 ET

Stoke Therapeutics Shares Rise Premarket on Key FDA Designation

WSJDec 4 07:39 ET

Express News | Stoke Therapeutics Inc - Phase 3 Registration Study Update Expected by Year-End

ReutersDec 4 07:00 ET

Express News | Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

ReutersDec 4 07:00 ET

Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 10,000 Shares

Quiver QuantitativeDec 3 16:18 ET

Stoke Therapeutics Announces Plans To Present New Data That Support Zorevunersen As Potentially The First Disease-Modifying Medicine For Dravet Syndrome At The American Epilepsy Society 2024 Annual Meeting

BenzingaDec 2 09:01 ET